Day: December 5, 2023

Zoom Celebrates its Fourth Consecutive Time in the Leaders Quadrant

SAN JOSE, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM), today announced that analyst firm Gartner has named Zoom a Leader in the 2023 Gartner® Magic Quadrant for Unified Communications as a Service (UCaaS), Worldwide for the fourth time in a row. The UCaaS report evaluated 11 companies in the unified communications space, and Zoom has been recognized as a Leader in this space for its UCaaS offerings. Zoom includes enterprise-grade solutions like Zoom Team Chat, Zoom Phone, Zoom Meetings, Zoom Contact Center, and Zoom AI Companion.

“We are excited to be named a Leader in the Gartner Magic Quadrant for UCaaS for the fourth consecutive year which we feel is a result of our ongoing commitment to offer an exceptional UCaaS experience,” said Graeme Geddes, Chief Growth Officer at Zoom. “As we continue to innovate and evolve our platform, we remain true to solving real customer problems and delivering limitless human connection.”

To read a complimentary copy of the 2023 Gartner Magic Quadrant for UCaaS report, please click here.

Gartner, Magic Quadrant for Unified Communications as a Service, Worldwide, Rafael Benitez, Megan Fernandez, Christopher Trueman, Pankil Sheth, 28 November 2023.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Public Relations
Bridget Moriarty
Corporate PR Manager
press@zoom.us

GlobeNewswire Distribution ID 8990024

KIGALI, Rwanda, Dec. 05, 2023 (GLOBE NEWSWIRE) — The 13^th International Conference on Typhoid & Other Invasive Salmonelloses gets under way today in Kigali, Rwanda, with nearly 350 researchers, healthcare professionals and policymakers meeting to find ways to address the urgent challenges of typhoid and other invasive salmonelloses.

The three-day conference, hosted by the Coalition against Typhoid (CaT), housed at the Sabin Vaccine Institute, is the largest convening of the typhoid research community. Titled “Catalysing Change: The Urgency of Expanding Impact-Driven Solutions,” it will feature 95 oral presentations and 120 poster presentations exploring opportunities for preventing and combating typhoid and invasive non-typhoid salmonella disease (iNTS).

Typhoid is a bacterial infection contracted through the consumption of food or beverages contaminated with Salmonella Typhi. There are an estimated 9-24 million cases of typhoid fever globally each year, leading to more than 110,000 deaths.

“These meetings have consistently fostered research collaborations and knowledge exchange that have been instrumental in advancing important progress within this field,” says Dr. Denise Garrett, Vice President, Applied Epidemiology at the Sabin Vaccine Institute. “Our aim is to address the current challenges in typhoid and iNTS control and prevention, discuss impactful tools and potential solutions, and collectively explore approaches to forge a pathway forward.”

Urgent issues in typhoid and iNTS control include:

• Escalating drug resistance, limiting treatment options for typhoid patients.
• The impact of climate change and extreme weather events, contributing to typhoid spread.
• Need for improved diagnostics to assess disease burden and to facilitate decision-making for the introduction of the typhoid vaccine into national immunization schedules.
• Need to improve water, sanitation and hygiene (WASH) infrastructure, such as water treatment or filtration, installation and management of sanitation systems, and education on proper handwashing to prevent the transmission of typhoid and other invasive salmonelloses.

The conference is supported by the Bill & Melinda Gates Foundation and will run through December 7.

For more information about the Coalition against Typhoid, visit: https://www.coalitionagainsttyphoid.org

For media inquiries: press@sabin.org

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policymakers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.

Sabin leads research projects generating estimates of the burden of enteric fever around the world and conducts typhoid vaccine immunogenicity, effectiveness, and impact studies. Sabin’s Surveillance for Enteric Fever in Asia Project (SEAP) tracks enteric fever in Bangladesh and Nepal to establish disease burden and the potential impact of vaccines. Additionally, Sabin leads the Sero-epidemiology and Environmental Surveillance (SEES) project, which has developed and validated sero-surveillance tools to rapidly estimate the burden of enteric fever in community settings.

About the Coalition against Typhoid (CaT)

The Coalition against Typhoid (CaT), based at the Sabin Vaccine Institute, works to prevent typhoid and other invasive salmonelloses through research, education, and advocacy. With more than 800 members, the Coalition acts as a catalyst in the global health community to coordinate partnerships, convene decision-makers, and advocate for sustainable solutions, including access to next-generation vaccines and clean water. The Coalition, formed in 2010, is guided by a multi-stakeholder steering committee. It is supported by the Bill & Melinda Gates Foundation.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 621-1691
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/edaaf20e-0b8f-4647-80a0-fa5995adacc3

GlobeNewswire Distribution ID 8989910

KIGALI, Rwanda, Dec. 05, 2023 (GLOBE NEWSWIRE) — The 13^th International Conference on Typhoid & Other Invasive Salmonelloses gets under way today in Kigali, Rwanda, with nearly 350 researchers, healthcare professionals and policymakers meeting to find ways to address the urgent challenges of typhoid and other invasive salmonelloses.

The three-day conference, hosted by the Coalition against Typhoid (CaT), housed at the Sabin Vaccine Institute, is the largest convening of the typhoid research community. Titled “Catalysing Change: The Urgency of Expanding Impact-Driven Solutions,” it will feature 95 oral presentations and 120 poster presentations exploring opportunities for preventing and combating typhoid and invasive non-typhoid salmonella disease (iNTS).

Typhoid is a bacterial infection contracted through the consumption of food or beverages contaminated with Salmonella Typhi. There are an estimated 9-24 million cases of typhoid fever globally each year, leading to more than 110,000 deaths.

“These meetings have consistently fostered research collaborations and knowledge exchange that have been instrumental in advancing important progress within this field,” says Dr. Denise Garrett, Vice President, Applied Epidemiology at the Sabin Vaccine Institute. “Our aim is to address the current challenges in typhoid and iNTS control and prevention, discuss impactful tools and potential solutions, and collectively explore approaches to forge a pathway forward.”

Urgent issues in typhoid and iNTS control include:

• Escalating drug resistance, limiting treatment options for typhoid patients.
• The impact of climate change and extreme weather events, contributing to typhoid spread.
• Need for improved diagnostics to assess disease burden and to facilitate decision-making for the introduction of the typhoid vaccine into national immunization schedules.
• Need to improve water, sanitation and hygiene (WASH) infrastructure, such as water treatment or filtration, installation and management of sanitation systems, and education on proper handwashing to prevent the transmission of typhoid and other invasive salmonelloses.

The conference is supported by the Bill & Melinda Gates Foundation and will run through December 7.

For more information about the Coalition against Typhoid, visit: https://www.coalitionagainsttyphoid.org

For media inquiries: press@sabin.org

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policymakers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X, @SabinVaccine.

Sabin leads research projects generating estimates of the burden of enteric fever around the world and conducts typhoid vaccine immunogenicity, effectiveness, and impact studies. Sabin’s Surveillance for Enteric Fever in Asia Project (SEAP) tracks enteric fever in Bangladesh and Nepal to establish disease burden and the potential impact of vaccines. Additionally, Sabin leads the Sero-epidemiology and Environmental Surveillance (SEES) project, which has developed and validated sero-surveillance tools to rapidly estimate the burden of enteric fever in community settings.

About the Coalition against Typhoid (CaT)

The Coalition against Typhoid (CaT), based at the Sabin Vaccine Institute, works to prevent typhoid and other invasive salmonelloses through research, education, and advocacy. With more than 800 members, the Coalition acts as a catalyst in the global health community to coordinate partnerships, convene decision-makers, and advocate for sustainable solutions, including access to next-generation vaccines and clean water. The Coalition, formed in 2010, is guided by a multi-stakeholder steering committee. It is supported by the Bill & Melinda Gates Foundation.

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 621-1691
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/edaaf20e-0b8f-4647-80a0-fa5995adacc3

GlobeNewswire Distribution ID 8989910

The battery energy storage system Coalburn 1 will be one of the largest battery storage projects in Europe. Construction has commenced in November 2023 and the project will be 500 MW / 1,000 MWh once complete.

COPENHAGEN, Denmark, Dec. 05, 2023 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners (CIP) through its Flagship Funds has taken final investment decision and commenced construction on a 500 MW / 1,000 MWh energy storage system in Coalburn, Scotland, which will be one of the largest of its kind in Europe.

The facility is the first project to be developed from the partnership between CIP and Alcemi to deploy 4 GW of energy storage assets across the UK. CIP aims to take final investment decision on two other projects next year with a combined capacity above 1 GW. The portfolio will provide vital support to the UK’s energy network, accelerating the integration of renewable energy and the transition to net zero by 2050.

The Coalburn 1 facility has been developed with extensive landscaping and ecological mitigation measures, including the maintenance of peat reserves, tree and wildflower planting, and new habitats, promoting biodiversity across the site.

The scheme will reduce the need for fossil fuel power generation during periods of peak demand leading to a decrease in CO2 emissions but also provide balancing services to help lower the costs for end consumers to manage the UK Power system.

“Achieving Final Investment Decision on one of the largest battery projects in Europe is a significant milestone for CIP. It demonstrates CIP’s industrial approach in identifying a market need and delivering a large-scale project with a robust contractual framework with high quality partners and counterparties. The integration of renewable energy into the energy system requires significant investment into storage solutions and we have a significant pipeline of storage projects across the world which we hope to build in the years ahead,” said Nischal Agarwal, partner at CIP.

Canadian Solar’s e-STORAGE will deliver their proprietary energy storage solution, SolBank, while H&MV Engineering will undertake the balance of plant works. SSE Energy Markets will provide the optimisation services for the project.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages 12 funds and has to date raised approximately EUR 26 billion for investments in energy and associated infrastructure from more than 150 international institutional investors. CIP has approximately 400 employees and 12 offices around the world. For more information, visit www.cip.com

For further information, please contact:

Simon Mehl Augustesen, Chief Communication Officer
Phone: +45 3052 6721
Email: siau@cip.dk

Thomas Kønig, Partner – Investor Relations
Phone: +45 7070 5151
Email: tkon@cip.dk

GlobeNewswire Distribution ID 1000902671

ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine.

This recognition acknowledges the contributions of Curia’s Aurangabad and Hyderabad sites. The Aurangabad facility provides contract manufacturing of active pharmaceutical ingredients (APIs) and intermediates, and the Hyderabad site includes the Hyderabad Research Center with expertise in medicinal chemistry and chemical and analytical development. These sites also house Curia’s quality control center and Global Shared Services (GSS) center, which support the company’s global organization, enabling process standardization and scalability.

Curia’s focus on continuous improvement for its comprehensive suite of services and investments in innovative technologies position the company as a strong partner to pharmaceutical and biotechnology companies across the drug research, development and manufacturing continuum. The report also highlights Curia’s commitment to being an employer of choice, providing employees with a workplace culture rich in opportunities for professional development and recognition.

“This achievement is a testament to the talent and hard work from our Aurangabad and Hyderabad facilities, and it is a well-deserved honor for the team,” said Philip Macnabb, CEO, Curia. “Our India sites relentlessly pursue excellence and are vital to our goal of improving patients’ lives.”

India Pharma Outlook’s editorial board compiled the list with a panel of judges with expertise in the industry, including CXOs and analysts. Winners were chosen for their impact on India’s economy through job creation, fostering research and development and for their high-quality offerings in the pharmaceutical and biotechnology industry.

About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 27 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/faac19ea-f26f-4811-946f-e03d10480984

GlobeNewswire Distribution ID 8989258

ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine.

This recognition acknowledges the contributions of Curia’s Aurangabad and Hyderabad sites. The Aurangabad facility provides contract manufacturing of active pharmaceutical ingredients (APIs) and intermediates, and the Hyderabad site includes the Hyderabad Research Center with expertise in medicinal chemistry and chemical and analytical development. These sites also house Curia’s quality control center and Global Shared Services (GSS) center, which support the company’s global organization, enabling process standardization and scalability.

Curia’s focus on continuous improvement for its comprehensive suite of services and investments in innovative technologies position the company as a strong partner to pharmaceutical and biotechnology companies across the drug research, development and manufacturing continuum. The report also highlights Curia’s commitment to being an employer of choice, providing employees with a workplace culture rich in opportunities for professional development and recognition.

“This achievement is a testament to the talent and hard work from our Aurangabad and Hyderabad facilities, and it is a well-deserved honor for the team,” said Philip Macnabb, CEO, Curia. “Our India sites relentlessly pursue excellence and are vital to our goal of improving patients’ lives.”

India Pharma Outlook’s editorial board compiled the list with a panel of judges with expertise in the industry, including CXOs and analysts. Winners were chosen for their impact on India’s economy through job creation, fostering research and development and for their high-quality offerings in the pharmaceutical and biotechnology industry.

About Curia
Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 27 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/faac19ea-f26f-4811-946f-e03d10480984

GlobeNewswire Distribution ID 8989258